# Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer

> **NCT00710710** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 89 (actual)

## Conditions studied

- Pancreatic Neoplasms

## Interventions

- **DRUG:** BI 2536

## Key facts

- **NCT ID:** NCT00710710
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08-01
- **Primary completion:** 2008-10-14
- **Final completion:** 2008-10-14
- **Target enrollment:** 89 (ACTUAL)
- **Last updated:** 2022-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00710710

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00710710, "Open, Randomized Phase II Trial to Investigate the Efficacy and Safety of the PLK-1 Inhibitor BI 2536 in Patients With Advanced, Unresectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00710710. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*